[Studies on the usefulness of a long-term, high-dose treatment of methylcobalamin in patients with oligozoospermia]

Hinyokika Kiyo. 1987 Jan;33(1):151-6.
[Article in Japanese]


Methylcobalamin (CH3-B12) was administrated in a dose of 6 mg per day (group A, 16 cases) or 12 mg per day (group B, 23 cases) for 16 weeks to patients with oligozoospermia. There was no difference between group A and group B regarding vitamin B12 concentrations in the serum or seminal fluid. CH3-B12 appeared to be transported to seminal fluid very efficiently. However, results from group A and group B did not differ with respect to this parameter. The efficacy rate for group A was 37.5% and that for group B was 39.1%. From these results, it was concluded that a long-term, high dose treatment of CH3-B12 was useful for the treatment of patients with oligozoospermia. Since the efficacy rates were not different between the two groups, 6 mg per day would be the recommended dose. Clinical adverse reactions were observed in one patient in each group. Drug-related laboratory adverse reactions were observed in only one patient in group B.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Follicle Stimulating Hormone / blood
  • Humans
  • Luteinizing Hormone / blood
  • Male
  • Oligospermia / blood
  • Oligospermia / drug therapy*
  • Sperm Count
  • Vitamin B 12 / administration & dosage
  • Vitamin B 12 / analogs & derivatives*
  • Vitamin B 12 / blood
  • Vitamin B 12 / therapeutic use


  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • mecobalamin
  • Vitamin B 12